The Scripps Research Institute (TSRI) and the California Institute for Biomedical Research (Calibr) two leading non-profit research organizations announced the signing of a strategic affiliation that combines the two organizations into a new biomedical research entity with the tools and know-how to rapidly translate its scientific discoveries into life-saving medicines for the public benefit.
This integration of basic scientific and translational research will reduce the costs and timelines associated with the crucial early stages of drug development, and lead to the creation of a self-sustaining model for non-profit research in which drug development successes drive the funding of new scientific discoveries and medicines many years into the future.
The union of these two non-profit organizations both led by Peter Schultz, Ph.D. provides the ability to rapidly move the basic scientific research carried out at TSRI into Calibr, whose expertise and infrastructure can accelerate drug development from discovery through early clinical trials, complementing the pharmaceutical industry's increasing focus on the later stages of clinical development.
As part of the formal affiliation, the two organizations will now share a combined Board of Directors, as well as scientific and administrative resources that will be consolidated over time. Schultz is overseeing the integration of the two institutes' distinct cultures and operations. Both institutes will continue to collaborate with their other partners in the academic and commercial sectors.
TSRI is internationally recognized for its scientific impact in the fields of chemistry, structural and molecular biology, immunology and neuroscience, and for its many scientific breakthroughs that have led to therapies that address infant respiratory distress, rheumatoid arthritis, lupus, hemophilia and blood cancers.
Each of the ten regulatory agency-approved medicines emerging from TSRI took an average of more than 20 years to move from drug discovery to market availability. The new affiliation between TSRI and Calibr aspires to accelerate that timeline, as well as to increase the number of basic science discoveries that are translated into first-in-class drugs.
Founded in 2012, Calibr has leveraged its strengths in small molecule discovery, protein engineering, and translational research through collaborations with academic, foundation and industry partners. To date, Calibr has generated a pipeline of candidate medicines for a number of disease areas including new approaches to osteoarthritis, tuberculosis, childhood diarrhea, heart disease, fibrosis, multiple sclerosis and cancer creating opportunities to move five to 10 new molecules into the clinic within the next two years.
The two organizations have already successfully collaborated on several research programs in recent years, including the development of an antibody engineering platform that could improve treatments for chronic diseases such as diabetes and COPD, and innovative immune therapies for the treatment of cancer. These collaborations have led to several candidate therapies, two of which Calibr has partnered with major pharmaceutical companies. Moreover, these collaborations are providing a unique training environment for students and fellows at the interface of basic and translational research, resulting in high-impact publications, and preparing them to tackle some of the most important biomedical challenges in academia and industry.